Tetracyclines in COVID-19 patients quarantined at home: Literature evidence supporting real-world data from a multicenter observational study targeting inflammatory and infectious dermatoses.
Laura Cristina GironiGiovanni DamianiElisa ZavattaroAlessia PacificoPierachille SantusPaolo Daniele Maria PigattoOttavio CremonaPaola SavoiaPublished in: Dermatologic therapy (2020)
Tetracyclines (TetraC) are widely used in dermatology for both inflammatory and infectious dermatoses; recently both in vivo and in vitro studies started to suggest also a potential antiviral effect. During COVID-19 outbreak, several dermatological patients contracted SARS-CoV-2 experiencing only mild symptoms, but no protocol were approved. A multicenter prospective observational study that enrolled COVID-19 patients visited with teledermatology and undergoing TetraC was performed. About 38 adult outpatients (M/F: 20/18, age 42.6 years [21-67]) were enrolled. During the TetraC treatment, symptoms resolved in all patients within 10 days. Remarkably, ageusia and anosmia disappeared in the first week of TetraC treatment. TetraC seem a promising drug to treat COVID-19 outpatients with mild symptoms.
Keyphrases
- sars cov
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- systematic review
- oxidative stress
- randomized controlled trial
- peritoneal dialysis
- coronavirus disease
- respiratory syndrome coronavirus
- emergency department
- electronic health record
- cancer therapy
- physical activity
- young adults
- depressive symptoms
- big data
- deep learning
- replacement therapy
- drug induced